Ono Pharmaceutical (OTCMKTS:OPHLF) Raised to “Strong-Buy” at Zacks Research

Ono Pharmaceutical (OTCMKTS:OPHLF) was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Ono Pharmaceutical Stock Up 4.4%

Shares of Ono Pharmaceutical stock opened at $15.56 on Monday. Ono Pharmaceutical has a 1 year low of $10.06 and a 1 year high of $18.67. The firm has a market cap of $7.31 billion, a price-to-earnings ratio of 15.72 and a beta of 0.34. The company has a 50-day moving average of $14.40 and a 200 day moving average of $14.67. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.